On December 22, 2025, the U.S. Food and Drug Administration granted approval for an oral formulation of semaglutide for chronic weight management, marking the first pill-based GLP-1 therapy for obesity. Developed by Novo Nordisk, this approval was based on data from the Phase 3 OASIS 4 trial published in the New England Journal of Medicine, which showed a mean weight loss of 13.6% over approximately 64 weeks in the intention-to-treat population versus 2.2% for placebo. The company plans a full U.S. launch in early January 2026, and has outlined administration guidelines requiring fasting and specific dosing instructions to ensure optimal absorption, as detailed in the FDA-reviewed label.

Facing patent expiry in China in March 2026 and emerging local generics, Novo Nordisk cut local list prices for its highest‐dose Wegovy pens by roughly 50% in provinces such as Yunnan and Sichuan, reducing monthly costs to approximately 987–1,284 yuan according to government procurement documents. Concurrently, the company launched Ozempic pens in India at weekly prices equivalent to $24.35 for the 0.25 mg dose, with 0.5 mg and 1 mg strengths priced at 8,800 and 11,175 rupees per month respectively. These moves aim to preserve market share in two of the world’s largest obesity markets and set pricing benchmarks ahead of generic entrants.

Following the oral semaglutide approval, Novo Nordisk shares surged by up to 8% in a single trading session, reflecting investor optimism about expanding patient reach through a non-injectable format. However, competitive pressure remains elevated: Eli Lilly’s tirzepatide-based Zepbound continues to gain share in the obesity segment, and third-party compounding pharmacies offer lower-cost semaglutide alternatives. Looking ahead, investors will monitor uptake rates for the oral pill, ongoing pipeline developments such as next-generation combination therapies, and the impact of region-specific pricing strategies on Novo Nordisk’s global weight-management franchise.